Charles Bennett to Rituximab
This is a "connection" page, showing publications Charles Bennett has written about Rituximab.
Connection Strength
1.890
-
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
Score: 0.724
-
Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol. 2016 Jan; 95(1):27-33.
Score: 0.482
-
Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update. Cancer Treat Res. 2022; 184:103-111.
Score: 0.186
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.173
-
Pharmacovigilance and PML in the oncology setting. Cleve Clin J Med. 2011 Nov; 78 Suppl 2:S13-7.
Score: 0.092
-
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 Aug; 10(8):816-24.
Score: 0.079
-
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40.
Score: 0.077
-
Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma. 2009 Mar; 50(3):323-4.
Score: 0.077